NCT06237400View on ClinicalTrials.gov

A Study of ZG19018 in Patients With KRAS G12C Mutant Advanced Solid Tumors.

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

110

Participants

Timeline

Start Date

May 26, 2022

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2025

Conditions

KRAS G12C Mutant Advanced Solid Tumors

Interventions

DRUG

ZG19018

ZG19018 Given by PO (mouth)

Trial Locations (1)

100853

RECRUITING

Chinese PLA General Hospital, Beijing

All Listed Sponsors

lead

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

INDUSTRY